Ozempic: Semaglutide for Type 2 Diabetes
Written by Dan Cripe, RN, BSN & Marcia Cripe, RN | Last Updated: September 15, 2026
Ozempic stimulates insulin secretion primarily when your blood glucose is elevated, which is one of the most important differences between semaglutide and medications such as sulfonylureas or injected insulin. That glucose-dependent action allows Ozempic to lower fasting and post-meal glucose with a relatively low intrinsic risk of hypoglycemia when it is used without medications that independently drive glucose lower.
Ozempic contains semaglutide, a once-weekly GLP-1 receptor agonist approved for adults with type 2 diabetes. Its role now extends well beyond A1C reduction: current U.S. labeling includes reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, as well as reduction of sustained kidney-function decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
That broader evidence has changed where semaglutide fits in diabetes treatment. In 2026, the decision to use a GLP-1 receptor agonist is no longer based only on whether metformin has failed or whether A1C remains above target; cardiovascular disease, chronic kidney disease, obesity, hypoglycemia risk, treatment burden, and patient preference can all influence medication selection.
If you have prediabetes or metabolic syndrome without established type 2 diabetes, however, Ozempic's diabetes indication does not automatically apply to you. Ozempic is not FDA-approved simply for prediabetes or metabolic syndrome, and its use should not be presented as though those diagnoses are interchangeable with type 2 diabetes.
The Incretin Cascade: Beta-Cell Stimulation, Glucagon Suppression, and Liver Output
Semaglutide mimics part of the activity of the naturally occurring hormone GLP-1, or glucagon-like peptide-1. GLP-1 receptors are found in several tissues involved in glucose regulation, including pancreatic beta cells, where receptor activation increases cyclic AMP signaling and enhances insulin release when glucose is elevated.
This is not continuous, indiscriminate insulin secretion. As glucose falls, the insulin-stimulating effect diminishes, which helps explain why Ozempic alone does not behave like injected insulin or a sulfonylurea.
Semaglutide also influences pancreatic alpha-cell function by reducing inappropriate glucagon secretion when glucose is elevated. Glucagon ordinarily tells the liver to release glucose, so reducing excessive glucagon signaling helps decrease unnecessary hepatic glucose output during periods when circulating glucose is already high.
The result is a coordinated metabolic effect rather than a single glucose-lowering mechanism. Your pancreas responds more appropriately to glucose, glucagon signaling becomes more appropriate, gastric emptying is altered, and food intake often decreases as central appetite pathways respond to GLP-1 receptor activation.
How Fast Does Ozempic Lower Blood Sugar?
Ozempic begins producing pharmacologic effects before your A1C has time to change meaningfully. After a subcutaneous injection, semaglutide reaches its maximum concentration roughly one to three days later, so fasting or post-meal glucose readings can begin changing during the early weeks of treatment.
That does not mean your final glucose response can be judged after one injection. Semaglutide has an approximately one-week half-life and reaches steady-state exposure after several weeks of weekly dosing, while the first four weeks are intentionally spent at the 0.25-mg initiation dose.
A1C introduces another delay because it reflects glucose exposure over approximately the previous two to three months, with greater influence from more recent weeks. Your home glucose readings or CGM may therefore improve before your laboratory A1C fully reflects what the medication is doing.
For practical purposes, early glucose changes can appear within days to weeks, steady-state semaglutide exposure develops over roughly four to five weeks, and the full A1C picture becomes clearer over the following several months as treatment is titrated and red blood cells reflect the newer glucose environment.
Why Fasting Glucose May Improve Before Your A1C Fully Catches Up
Fasting glucose is a measurement of what is happening at one moment. A1C is an integrated marker of glucose exposure over a much longer period.
That means your morning glucose can move from 170 mg/dL toward 120 mg/dL long before your A1C has had enough time to reflect that change. Post-meal glucose patterns can also continue evolving as dose exposure increases and eating patterns change.
If you are using a glucose meter or CGM, those data can therefore provide useful information during titration that A1C alone cannot provide. This is especially important if you also use insulin or a sulfonylurea, because improving daily glucose can create hypoglycemia risk before your next scheduled A1C test shows the full magnitude of the change.
A1C Reductions: What the SUSTAIN Clinical Trials Show
Ozempic's A1C effect varies substantially according to baseline A1C, dose, background medications, diabetes duration, and study population. Someone starting at an A1C of 10% has more room for reduction than someone starting at 7.6%, so there is no single number that every person should expect.
Across the SUSTAIN program, semaglutide 0.5 mg commonly reduced A1C by roughly 1.2 to 1.5 percentage points, while the 1-mg dose frequently produced reductions around 1.5 to 1.9 percentage points in inadequately controlled populations.
The 2-mg dose can produce still larger changes. In SUSTAIN FORTE, participants began with an average A1C of 8.9%; at 40 weeks, A1C fell approximately 2.2 percentage points with semaglutide 2 mg and 1.9 points with 1 mg under the trial-product estimand.
That means the frequently quoted “Ozempic lowers A1C by 1% to 1.5%” rule is useful only as a rough generalization. The actual response can be smaller or considerably larger.
Clinical Efficacy and Dose Context
These are trial ranges, not dose guarantees. A1C response should be interpreted in the context of your starting A1C and the other treatments you use.
Ozempic vs. Sitagliptin: SUSTAIN-2
SUSTAIN-2 compared once-weekly semaglutide with the DPP-4 inhibitor sitagliptin in adults whose type 2 diabetes remained inadequately controlled on metformin, a thiazolidinedione, or both.
At 56 weeks, A1C fell approximately 1.3 percentage points with semaglutide 0.5 mg and 1.6 points with semaglutide 1 mg, compared with approximately 0.5 points with sitagliptin.
Semaglutide also produced substantially greater weight reduction. The study helped establish that direct GLP-1 receptor agonism could produce stronger glycemic and weight effects than prolonging the activity of native incretin hormones through DPP-4 inhibition.
Ozempic vs. Exenatide ER: SUSTAIN-3
SUSTAIN-3 compared semaglutide 1 mg weekly with once-weekly extended-release exenatide.
A1C decreased approximately 1.5 percentage points with semaglutide versus 0.9 points with exenatide ER at 56 weeks. Average weight loss was also greater with semaglutide: approximately 5.6 kg compared with 1.9 kg.
About 67% of semaglutide-treated participants reached an A1C below 7%, compared with 40% receiving exenatide ER.
Those findings demonstrated that medications within the same broad GLP-1 class can differ meaningfully in potency.
Ozempic vs. Insulin Glargine: SUSTAIN-4
SUSTAIN-4 compared semaglutide with titrated basal insulin glargine in insulin-naive adults inadequately controlled on metformin, with or without a sulfonylurea.
At 30 weeks, A1C fell approximately 1.21 percentage points with semaglutide 0.5 mg and 1.64 points with semaglutide 1 mg, compared with approximately 0.83 points with insulin glargine.
The weight difference moved in opposite directions. Participants receiving semaglutide lost approximately 3.5 to 5.2 kg, while those receiving insulin glargine gained about 1.2 kg.
Hypoglycemia was also less frequent in the semaglutide groups than in the insulin-glargine group, although background sulfonylurea use remained an important risk factor.
That does not mean Ozempic can universally replace insulin. People with substantial beta-cell failure, severe hyperglycemia, catabolic symptoms, acute illness, or other specific clinical situations may still require insulin.
Cardiovascular Protection: What SUSTAIN-6 Showed
SUSTAIN-6 changed the Ozempic story from glucose lowering alone to cardiovascular outcomes.
The trial enrolled adults with type 2 diabetes who were at high cardiovascular risk and compared once-weekly semaglutide with placebo in addition to standard treatment.
The primary composite outcome included cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
That outcome occurred significantly less often with semaglutide, corresponding to an approximately 26% relative risk reduction in three-point MACE.
The result ultimately supported Ozempic's FDA indication to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
This distinction matters because cardiovascular benefit is not simply a side effect of achieving a lower A1C. Current diabetes treatment increasingly selects medications based on demonstrated cardiovascular outcomes, sometimes regardless of whether additional glucose lowering is needed.
Cardiovascular Benefit Is Not Just an A1C Story
Semaglutide influences several factors that can contribute to cardiovascular risk, including body weight, blood pressure, glucose exposure, inflammatory signaling, and other metabolic measures.
However, it is difficult to assign the cardiovascular benefit to one single pathway. Weight loss, glycemic improvement, blood-pressure changes, renal effects, vascular biology, and direct GLP-1 receptor signaling may all contribute.
That is why the most defensible statement is the clinical one: in a randomized cardiovascular-outcomes trial, semaglutide reduced major cardiovascular events in an appropriate high-risk type 2 diabetes population.
The trial result is stronger evidence than trying to prove that one isolated physiologic mechanism explains the entire benefit.
Kidney Protection: What FLOW Added
The FLOW trial moved semaglutide's kidney evidence from suggestive secondary endpoints into a dedicated kidney-outcomes trial.
FLOW enrolled more than 3,500 adults with type 2 diabetes and chronic kidney disease and randomized them to semaglutide 1 mg weekly or placebo on top of standard care.
The primary composite included major kidney outcomes such as kidney failure, a sustained reduction in eGFR, or death from kidney or cardiovascular causes.
The primary outcome occurred less frequently with semaglutide, corresponding to an approximately 24% relative risk reduction. Semaglutide also reduced all-cause mortality and cardiovascular events while slowing loss of kidney function.
Those findings led to a major expansion of the Ozempic label. Ozempic is now indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
For this indication, the current label directs titration to 1 mg once weekly after at least four weeks on 0.5 mg.
How Ozempic Protects the Kidney
It is tempting to reduce FLOW to one mechanism such as “semaglutide lowers intraglomerular pressure,” but the kidney benefit is probably multifactorial.
Better glucose control, lower body weight, blood-pressure effects, reduced albuminuria, vascular changes, inflammatory pathways, and direct or indirect renal effects may all contribute.
The important clinical result is that kidney outcomes improved even in a population already receiving contemporary CKD care. Later FLOW analyses have shown that the benefit persisted across broad ranges of baseline kidney-function severity.
That is substantially stronger evidence than simply observing a lower urine albumin measurement during an ordinary glucose-lowering trial.
Blood Pressure and Other Cardiometabolic Changes
Semaglutide trials commonly show modest reductions in systolic blood pressure alongside weight and glucose changes.
Those improvements are useful, but Ozempic is not a blood-pressure medication and should not replace appropriate antihypertensive treatment.
Likewise, improvements in weight, triglycerides, inflammation, and other biomarkers contribute to the broader metabolic picture without becoming separate indications for the drug.
The practical point is that a medication initially prescribed to lower glucose may influence several systems that contribute to long-term diabetic complications.
The Ozempic Dosing Ladder: From Initiation to 2 mg
Ozempic begins at 0.25 mg once weekly for four weeks.
The 0.25-mg dose is an initiation dose intended to reduce gastrointestinal adverse effects while your body adapts to semaglutide. The current prescribing information explicitly states that it is not effective for glycemic control.
At week five, the dose increases to 0.5 mg once weekly.
If additional glycemic control is needed after at least four weeks at 0.5 mg, the dose may be increased to 1 mg once weekly. If additional control is still needed after at least four weeks at 1 mg, the dose may increase to the maximum Ozempic dose of 2 mg once weekly.
That creates a minimum escalation pathway of:
0.25 mg → 0.5 mg → 1 mg → 2 mg.
The important phrase is “if additional glycemic control is needed.” The existence of a higher dose does not mean every person should automatically progress to 2 mg.
Why Ozempic Is Titrated Slowly
The escalation schedule is primarily about tolerability.
Semaglutide commonly causes nausea, vomiting, diarrhea, abdominal pain, and constipation, particularly during initiation and dose escalation.
The lower starting dose gives the gastrointestinal system and central nausea pathways time to adapt before therapeutic exposure increases.
Describing this as preventing “area postrema emetic shock” would overstate the mechanism and make a standard titration process sound more dangerous than it is. The clinically useful explanation is simply that gradual escalation reduces the likelihood that gastrointestinal adverse effects become intolerable.
How to Use the Ozempic Pen
Ozempic can be injected once weekly at any time of day, with or without meals, into the abdomen, thigh, or upper arm.
The traditional multidose Ozempic pens require a new disposable needle for each injection. When starting a new pen, the manufacturer's Instructions for Use include a flow check before the first injection from that pen; that flow check is not the same thing as routinely wasting medication before every weekly dose.
Different Ozempic strengths come in different pen presentations, and current U.S. labeling also includes certain single-dose prefilled syringe presentations. Because packaging and devices can change over time, you should identify your dose by the printed strength and follow the Instructions for Use that came with the actual product rather than relying on pen colors alone.
Never share an Ozempic pen between patients, even if the needle has been changed.
Combining Ozempic With Metformin
Metformin and Ozempic can be used together and often are.
The medications act through different mechanisms. Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, while semaglutide works through GLP-1 receptor signaling to enhance glucose-dependent insulin secretion, regulate glucagon, reduce food intake, and produce other metabolic effects.
Using them together can therefore provide complementary glucose lowering.
Metformin does not usually create meaningful hypoglycemia by itself, so combining metformin with Ozempic generally does not create the same low-glucose concern seen with insulin or sulfonylureas.
There is also no universal rule that metformin must be discontinued once Ozempic works well. Whether it remains useful depends on your kidney function, tolerability, glycemic goals, other conditions, and overall treatment plan.
Combining Ozempic With SGLT2 Inhibitors
Ozempic can also be used with an SGLT2 inhibitor when clinically appropriate.
That combination is particularly relevant in modern diabetes care because GLP-1 receptor agonists and SGLT2 inhibitors have partially complementary cardiovascular and kidney benefits.
For someone with type 2 diabetes plus chronic kidney disease or established cardiovascular disease, modern treatment may intentionally include more than one medication with proven organ-protective effects rather than trying to make one drug do everything.
The combination still requires individualized review of kidney function, hydration, blood pressure, infection risk, ketoacidosis risk from SGLT2 inhibition, and overall treatment burden.
Taking Ozempic With Insulin or a Sulfonylurea
This is where hypoglycemia deserves much closer attention.
Ozempic by itself has a relatively low intrinsic risk of true hypoglycemia because its insulin-stimulating effect is glucose dependent. Insulin and sulfonylureas such as glipizide, glimepiride, and glyburide can continue lowering glucose even when your glucose is already approaching or falling below target.
When semaglutide improves glycemic control and appetite decreases, the insulin or secretagogue dose that previously matched your glucose and food intake may become excessive.
Current Ozempic labeling therefore states that reducing the dose of insulin or an insulin secretagogue may be necessary when Ozempic is used with them.
There is no universal rule that everyone should automatically reduce insulin by 10%, 20%, or any other fixed percentage when Ozempic starts. That decision depends on baseline A1C, current insulin dose, fasting and post-meal readings, CGM trends, kidney function, hypoglycemia history, food intake, and whether the insulin is basal, mealtime, or both.
Hypoglycemia Signs You Should Recognize
Hypoglycemia can cause sweating, tremor, palpitations, hunger, dizziness, weakness, irritability, difficulty concentrating, or confusion. More severe hypoglycemia can cause seizures or loss of consciousness and requires urgent treatment.
If you use insulin or a sulfonylurea, falling glucose readings after Ozempic initiation should prompt reassessment of the treatment plan rather than being interpreted as proof that stronger glucose lowering is always better.
For most alert adults with glucose at or below 70 mg/dL, the traditional treatment is 15 grams of fast-acting carbohydrate followed by a glucose recheck after 15 minutes. If glucose remains low, treatment is repeated.
Pure glucose tablets or gel, juice, or regular soda work faster than high-fat foods such as chocolate or peanut butter. Fat and protein can slow carbohydrate absorption, which is why they are poor first choices when glucose needs to rise quickly.
If a person is unconscious, having a seizure, or cannot safely swallow, oral carbohydrate should not be given. Glucagon should be used when available and emergency assistance obtained.
Ozempic and Diabetic Retinopathy
SUSTAIN-6 identified an increased rate of diabetic-retinopathy complications in semaglutide-treated participants, particularly among people who already had retinopathy and experienced large, rapid improvements in glucose.
This phenomenon is not unique to semaglutide. Rapid correction of chronic hyperglycemia has long been associated with temporary worsening of diabetic retinopathy in some people.
Current Ozempic labeling therefore says that patients with a history of diabetic retinopathy should be monitored for progression.
That does not translate into a universal requirement that every person starting Ozempic obtain a special ophthalmology examination immediately before each dose escalation. If you already have diabetic retinopathy, however, particularly proliferative disease or previous retinal treatment, your diabetes and eye-care clinicians may reasonably coordinate closer monitoring while A1C falls.
New flashes, a sudden increase in floaters, new visual distortion, a curtain-like loss of vision, or sudden vision loss require prompt ophthalmologic evaluation.
Ozempic Is Not Automatically “First-Line” for Every Person With Type 2 Diabetes
Older diabetes algorithms often presented treatment as a simple sequence: diagnose type 2 diabetes, start metformin, and add another medication only when metformin stops being enough.
Modern diabetes treatment is more individualized.
The 2026 ADA Standards recommend a person-centered medication strategy that considers cardiovascular disease, chronic kidney disease, heart failure, obesity, hypoglycemia risk, cost, tolerability, treatment goals, and personal preferences.
For people with established or high cardiovascular risk or CKD, a GLP-1 receptor agonist with proven cardiovascular or kidney benefit may be included irrespective of A1C and irrespective of whether metformin is being used.
That makes Ozempic a possible early treatment choice in selected patients without making it the universal first drug for every new diagnosis.
Navigating Insurance: Diagnosis, Labs, and Coverage
Ozempic's FDA diabetes indication is for type 2 diabetes, not simply weight loss, prediabetes, insulin resistance, or metabolic syndrome.
Standard diagnostic criteria for diabetes include an A1C of 6.5% or higher, fasting plasma glucose of 126 mg/dL or higher, a two-hour glucose of 200 mg/dL or higher during a 75-g oral glucose tolerance test, or a random glucose of at least 200 mg/dL in a person with classic symptoms or hyperglycemic crisis.
In the absence of unequivocal hyperglycemia, diagnosis generally requires confirmation with a second abnormal result.
Clinicians commonly code type 2 diabetes within the ICD-10 E11.x family, with the specific code depending on complications and clinical circumstances.
That diagnostic framework is not the same thing as an insurance prior-authorization rule.
Does Insurance Require Metformin Before Ozempic?
Sometimes, but not universally.
Commercial insurers, Medicare drug plans, Medicaid programs, employer plans, and pharmacy benefit managers can use different formularies and prior-authorization criteria. One plan may require documented type 2 diabetes alone, another may prefer a different GLP-1, and another may require previous use of metformin or another preferred medication.
Those rules also change over time.
That is why an article cannot accurately tell every reader, “Your insurer requires metformin failure before Ozempic.”
The more useful approach is to determine the exact denial reason from your plan. A missing diabetes diagnosis, step-therapy requirement, nonpreferred-drug rule, quantity limit, or formulary exclusion are different administrative problems with different possible next steps.
Why Accurate Documentation Matters
Your chart should accurately reflect why Ozempic is being prescribed.
If the indication is type 2 diabetes, relevant clinical documentation can include the diagnosis, laboratory history, A1C trajectory, current diabetes medications, prior treatment response, cardiovascular disease, kidney disease, hypoglycemia history, and other factors relevant to the prescription.
Documentation should not manufacture diabetes criteria merely to obtain coverage for weight management. Ozempic and Wegovy contain semaglutide, but they are separate products with different FDA indications and insurance pathways.
Accurate documentation protects both the patient and clinician while making it easier to determine what information an insurer actually needs.
Frequently Asked Questions About Ozempic for Diabetes
Can Ozempic cure type 2 diabetes?
Ozempic can produce substantial glucose improvement, and some people reach an A1C within the nondiabetes range while taking it. That does not mean the medication has cured type 2 diabetes because semaglutide is actively producing part of that glucose control.
True diabetes remission has a specific definition involving sustained glucose below the diabetes diagnostic threshold without glucose-lowering medication. If Ozempic is maintaining the lower A1C, the diabetes is being effectively treated rather than proven permanently absent.
How much does Ozempic lower A1C on average?
The answer depends on your starting A1C, dose, and background treatment. Across major SUSTAIN trials, 0.5 mg commonly produced reductions around 1.2%–1.5%, while 1 mg frequently produced reductions around 1.5%–1.9%.
In SUSTAIN FORTE, people starting with an average A1C of 8.9% had reductions of approximately 1.9% with 1 mg and 2.2% with 2 mg. Your individual result can be higher or lower than those averages.
How fast does Ozempic lower blood sugar?
Semaglutide begins acting after the first dose, and daily glucose readings can begin changing before A1C does. Drug exposure builds over several weeks, and the initiation dose is intentionally low, so the full therapeutic response develops progressively rather than appearing after the first injection.
A1C generally needs several months to reflect the newer glucose pattern fully, while CGM or fingerstick measurements can show changes much sooner.
Do I still need to check my blood sugar while taking Ozempic?
That depends on the rest of your diabetes treatment and your clinician's monitoring plan.
Glucose monitoring is especially important if you use insulin or a sulfonylurea because those medications create a higher risk of hypoglycemia as Ozempic improves glucose control. CGM can also be useful when medication changes are being made or when daily glucose patterns would help guide treatment.
Someone using Ozempic and metformin alone may not need the same testing frequency as someone on basal-bolus insulin.
Can I take Ozempic and metformin together?
Yes. They are commonly used together and work through different mechanisms.
Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, while Ozempic uses GLP-1 receptor signaling to enhance glucose-dependent insulin secretion, regulate glucagon, alter food intake, and improve other metabolic measures.
Whether you continue both long term depends on how well your diabetes is controlled and how well each medication is tolerated.
What if I take insulin too?
Ozempic can be used with insulin, but improving glucose control may make your existing insulin dose too strong.
Do not independently stop or substantially reduce insulin simply because you start Ozempic. Review glucose readings with the clinician managing your insulin so the regimen can be adjusted appropriately.
What should I do if my glucose drops below 70 mg/dL?
If you are awake and able to swallow, most adults should treat with approximately 15 grams of fast-acting carbohydrate, wait 15 minutes, and recheck the glucose. If it remains below 70 mg/dL, repeat treatment.
Glucose tablets or gel, juice, or regular soda are preferable to high-fat snacks because fat can delay carbohydrate absorption. If you cannot safely swallow or become unconscious, severe hypoglycemia requires glucagon when available and emergency help.
Does Ozempic protect the heart?
In adults with type 2 diabetes and established cardiovascular disease, Ozempic is FDA-approved to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.
That indication is supported by cardiovascular-outcomes evidence including SUSTAIN-6.
Does Ozempic protect the kidneys?
Ozempic now has a dedicated kidney indication for adults with type 2 diabetes and chronic kidney disease.
FLOW demonstrated a significant reduction in major kidney outcomes, and current U.S. labeling includes reduction of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in this population.
What Ozempic Changes About Type 2 Diabetes Treatment
Ozempic is more than a once-weekly way to lower an A1C number. Semaglutide improves glucose through coordinated insulin and glucagon effects, often reduces body weight, and now has randomized clinical-trial evidence supporting cardiovascular and kidney outcomes in major type 2 diabetes populations.
That does not make semaglutide the only medication that matters. Metformin, SGLT2 inhibitors, insulin, blood-pressure treatment, lipid therapy, nutrition, activity, and other interventions can remain essential parts of comprehensive diabetes care.
The practical goal is therefore not to reach the highest Ozempic dose or the lowest possible A1C simply because the medication can produce powerful effects. It is to use enough treatment to reach an individualized glycemic target while reducing cardiovascular and kidney risk without creating avoidable hypoglycemia or intolerable adverse effects.
When Ozempic works particularly well, the most important treatment question may eventually stop being, “Should I increase the semaglutide?” and become, “Do the insulin or sulfonylurea doses that were appropriate before Ozempic still make sense now?”
That is where glucose data, organ-protection evidence, and individualized diabetes management come together.
Ozempic vs. Wegovy: Same Molecule, Different Dosages and Approvals
Ozempic and Wegovy contain the same active molecule, but their indications and dosing are not identical.
Sources
- Novo Nordisk. Ozempic (semaglutide) U.S. Prescribing Information. Revised May 2026.
https://www.novo-pi.com/ozempic.pdf - American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
https://diabetesjournals.org/care/article/49/Supplement_1/S183/163934/9-Pharmacologic-Approaches-to-Glycemic-Treatment - American Diabetes Association. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
https://diabetesjournals.org/care/article/49/Supplement_1/S27/163926/2-Diagnosis-and-Classification-of-Diabetes - Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375:1834–1844.
https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 - Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024;391:109–121.
https://www.nejm.org/doi/full/10.1056/NEJMoa2403347 - Frías JP, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE). Lancet Diabetes & Endocrinology. 2021.
https://pubmed.ncbi.nlm.nih.gov/34293304/ - Ahrén B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on therapy in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes & Endocrinology. 2017.
https://pubmed.ncbi.nlm.nih.gov/28385659/ - Ahmann AJ, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3). Diabetes Care. 2018.
https://pubmed.ncbi.nlm.nih.gov/29246950/ - Aroda VR, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin with or without sulfonylureas (SUSTAIN 4). Lancet Diabetes & Endocrinology. 2017.
https://pubmed.ncbi.nlm.nih.gov/28344112/ - American Diabetes Association. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
https://diabetesjournals.org/care/article/49/Supplement_1/S132/163927/6-Glycemic-Goals-Hypoglycemia-and-Hyperglycemic - American Diabetes Association. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
https://diabetesjournals.org/care/article/49/Supplement_1/S216/163933/10-Cardiovascular-Disease-and-Risk-Management - American Diabetes Association. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1).
https://diabetesjournals.org/care/article/49/Supplement_1/S246/163914/11-Chronic-Kidney-Disease-and-Risk-Management - American Diabetes Association. A Practical Approach to Hypoglycemia Treatment. 2026.
https://diabetesjournals.org/compendia/article/2026/1/29/172316/Chapter-5-A-Practical-Approach-to-Hypoglycemia